What is the recommended dose of lidocaine (Anti-arrhythmic medication) in Advanced Cardiovascular Life Support (ACLS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ACLS Lidocaine Dosing for Cardiac Arrest

The recommended ACLS dose of lidocaine for shock-refractory VF/pVT is an initial dose of 1-1.5 mg/kg IV/IO, followed by a second dose of 0.5-0.75 mg/kg if needed. 1

Dosing Protocol for Lidocaine in ACLS

Initial Administration

  • First dose: 1-1.5 mg/kg IV/IO bolus
  • Second dose: 0.5-0.75 mg/kg IV/IO if needed

Clinical Context

Lidocaine is now considered equivalent to amiodarone as a first-line antiarrhythmic agent for shock-refractory ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT) according to the 2018 American Heart Association guidelines. This represents a change from previous guidelines which favored amiodarone as the first-line therapy 1.

Mechanism and Indications

Lidocaine is a Class Ib antiarrhythmic agent that:

  • Acts by blocking sodium channels with rapid kinetics
  • Is particularly effective in ischemic or depolarized tissue
  • Has minimal effect on normal cardiac tissue 2

Lidocaine is indicated in ACLS for:

  • Persistent VF/pVT despite defibrillation and epinephrine
  • Prevention of recurrence of VF/pVT
  • Control of unsustained ventricular ectopy requiring therapy
  • Treatment of wide-complex tachycardia of uncertain type 1

Important Considerations

Safety Concerns

  • Lidocaine is metabolized in the liver and its clearance is reduced in heart failure 1
  • Exceeding maximum recommended doses can lead to toxicity, including seizures 3
  • Careful dosing is particularly important in patients with hepatic dysfunction, advanced age, or hemodynamic compromise

Efficacy Considerations

While lidocaine is recommended in current ACLS protocols, it's important to note that:

  • CPR and defibrillation remain the only therapies consistently associated with improved survival in VF/pVT 1
  • Antiarrhythmic medications primarily show benefits in short-term outcomes such as ROSC or survival to hospital admission 1
  • The optimal sequence and timing of ACLS interventions, including antiarrhythmic administration, remains uncertain 1

Administration in the ACLS Algorithm

Lidocaine should be administered:

  • After defibrillation attempts have failed to convert VF/pVT
  • After epinephrine has been administered
  • Before or after the third shock in persistent or recurrent VF/pVT
  • Via IV or IO route when available

Remember that high-quality CPR with minimal interruptions and early defibrillation for shockable rhythms remain the cornerstones of effective resuscitation, with medications playing a supportive role in the ACLS algorithm.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Antiarrhythmic Drug Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.